Putnam Associates Study Finds Insurers Want More Prescription Drug Use

Putnam Associates released today the results of an intensive study of U.S. health insurance plans' perceptions of branded prescription drug use in the U.S. The study revealed that plans believe greater pharmacoeconomic value can be unlocked by increasing patient use within certain drug categories.

Rising healthcare expenses have insurance companies desperate to cut costs, and many worry this will prompt increasing restrictions across the board on patient prescription drug coverage. However, Putnam discovered 8 classes of drugs, accounting for over $100 billion in sales, where insurers believe that increasing the number of patients on therapies and getting those patients with prescriptions to take their drugs would create value for both patients and plans in the long term.

Plans' interest in seeing increased appropriate use suggests there is opportunity for pharmaceutical manufacturers to align with them on certain drug categories. "The common ground between health plans and pharmaceutical manufacturers is around appropriate use, as these conversations can unlock value and address needs for both parties," says Richard Tinsley, Partner at Putnam Associates. He adds, "Our study shows there is clear agreement and opportunity for expanded appropriate use in many categories while in others there is less agreement. One of the key challenges for a managed markets team is how to address these issues at a portfolio level."

Putnam Associates researchers spoke to health care plan decision-makers who collectively insure 62% of the privately insured U.S. population, or roughly 124 million individuals. Insurers were asked to consider both underuse and over use of branded prescription drugs across 18 drug categories. Of the 18 categories, 8 were identified as being underused.

To download a copy of "U.S. Managed Markets: Opportunities and Risks in the Emerging Appropriate Use Paradigm" visit http://www.putassoc.com/company/pub_usmanaged.html

Most Popular Now

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Sanofi to provide manufacturing support to Johnson…

Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, u...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Sanofi and GSK initiate new Phase 2 study of their…

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Ph...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...